ANAB

Over the past six months, several events have impacted AnaptysBio, Inc.'s stock price. A 10 to 15 stock split was reported as of April 20, 2026. The company completed the spin-off of its biopharma operations into a new public company, First Tracks Biotherapeutics, on April 20, 2026, marking a significant business model shift towards royalty and collaboration management. On September 21, 2026, AnaptysBio reported a profit for Q2 2026, primarily due to a one-time $181.5 million tax benefit from the release of a deferred-tax valuation allowance related to the First Tracks Biotherapeutics spin-off. In August 2026, GSK's Jemperli received an FDA Priority Tag for rectal cancer, with a decision anticipated in February 2027, following promising interim Phase II AZUR-1 data reported in July 2026. On September 30, 2026, JPMorgan maintained an 'Overweight' rating but reduced its price target from $70 to $60, while on October 4, 2026, Wall Street Zen downgraded the stock from 'Buy' to 'Hold,' contributing to a roughly 4.7% stock price drop. The Jemperli royalty stream is currently subject to litigation, with a post-trial hearing scheduled for October 20, 2026, and a judgment expected in late 2026 or early 2027. The stock has also been influenced by general market trends, including rising Treasury yields and tech sector sell-offs.